Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Outcomes Post-AlloSCT in DHL/DEL Lymphomas

Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Allogeneic stem cell transplantation (alloSCT) should be considered in patients with double-expressor lymphomas (DEL) and double-hit lymphomas (DHL), researchers concluded after conducting a retrospective analysis involving 78 individuals. Participants underwent alloSCT for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Investigators looked at the impact of DEL/DHL status. Among the results:

  • 47% had DEL and 13% DHL.
  • 4-year progression-free and overall survival rates were similar in patients with and without either DEL or DHL.
  • The findings held up after multivariate analysis, though researchers acknowledged the sample size might have prevented detecting significant differences.


Herrera A, Rodig S, Song J, et al. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. [Published online ahead of print November 28, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.11.023.

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Aggressive Lymphomas

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505

ADC + BR improves response rate in diffuse large B-cell lymphoma, Sehn LH et al. EHA Congress, Abstract S802.